A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer

Boring, 1993, Cancer statistics 1993, CA Cancer J Clin, 43, 7, 10.3322/canjclin.43.1.7 Harris, 1983, Hormonal therapy and chemotherapy of renal cell carcinoma, Semin Oncol, 10, 422 Hahn, 1978, Phase 11 study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer, Cancer Treat Rep, 62, 1093 Hahn, 1979, Phase II study of single agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer, Cancer Treat Rep, 63, 513 Hahn, 1981, Phase II study of vinblastineCCNU, triazinate, and dactinomycin in advanced renal cell cancer, Cancer Treat Rep, 65, 711 Earhart, 1983, Phase II study of PALA and AMSA in advanced renal cell carcinoma, Am J Clin Oncol, 6, 555, 10.1097/00000421-198310000-00008 Elson, 1987, Phase If studies of PCNU and bisantrene in advanced renal cell carcinoma, Cancer Treat Rep, 71, 331 Elson, 1988, Phase 11 trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivisin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma, Invest New Drugs, 6, 97, 10.1007/BF00195367 Creagan, 1991, A randomized prospective assessment of recombinant leukocyte A interferon with and without aspirin in advanced renal cell adenocarcinoma, J Clin Oncol, 9, 2104, 10.1200/JCO.1991.9.12.2104 Muss, 1987, Recombinant alfa interferon in renal cell carcinoma: A randomized trial of two routes of administration, J Clin Oncol, 5, 286, 10.1200/JCO.1987.5.2.286 Minasian, 1993, Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up, J Clin Oncol, 11, 1368, 10.1200/JCO.1993.11.7.1368 Atkins, 1993, Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma, J Clin Oncol, 11, 661, 10.1200/JCO.1993.11.4.661 Figlin, 1992, Concomitant administration of recombinant interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma, J Clin Oncol, 10, 41421, 10.1200/JCO.1992.10.3.414 Alberts, 1979, Kinetics of intravenous melphalan, Clin Pharmacol Therapy, 26, 73, 10.1002/cpt197926173 Alberts, 1984, Minimal melphalan (L -PAM) systemic availability (SA): Potential cause for failure of adjuvant breast cancer therapy trials, 3, 38 Rohrbaugh, 1982, Toxicity of cyclic intravenous melphalan (IVM) in children with refractory malignancies, 1, 12 Kovach, 1986, Phase I trial of parenteral 6-thioguanine given over 5 consecutive days, Can Research, 46, 5959 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Elson, 1988, Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma, Cancer Research, 48, 7310 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452